With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
The latest business developments from across Asia by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising
potential for other companies to move into export markets.
Data Shows 50% of New Trials Have Sites in Asia Pacifi c
Novotech, the Asia Pacifi c centred biotech specialist CRO said the latest industry research publication by GlobalData and Novotech found almost 50% of new trials had sites in Asia Pacifi c.
According to the new publication titled ‘State of the Global Biotech Landscape: Where the Opportunities Lie’, demand for Asia Pacifi c trial sites is strong with almost half of the more than 27,000 clinical trials initiated in 2021 having sites in Asia Pacifi c. The data shows almost 12,900 of the new trials had sites in Asia Pacifi c.
The report also noted that the Asia Pacifi c region, which has more than 6,772 trial sites each with access to an average of 2,136 million people, has considerable underutilised capacity presenting an opportunity for growth in multinational trials in the region.
In addition, analysis of trial growth trends found that Asia Pacifi c has also seen high phase-level growth over the 5-year analysis period to 2022.
Phases I and II were dominated by Asia Pacifi c, which served as a trial location in 57% and 49% of trials, respectively
US and EU remained stable at approximately 20% at phases I through III.
RoW representation is low in phases I and II but on par with the US and EU in phase III
Novotech was awarded the Frost & Sullivan Company of the Year Award 2022 for Best Practices in the Asia-Pacifi c contract research organisation industry. Novotech has
been a recipient of the Frost & Sullivan Asia Pacifi c Best Practices awards since 2006. Frost & Sullivan identifi es companies that consistently develop growth strategies based on a visionary understanding of the future, and effectively address new challenges and opportunities.
In response to the Company of the Year Award announcement, Novotech CEO Dr John Moller said this award is a credit to our entire global team which has decades of biotech drug development experience. “Our global clients benefi t from access to our expert teams in Asia Pacifi c, which is the fastest-growing clinical trial region, due to its vast patient populations and sophisticated medical research infrastructure. Our consistent investment in advanced training and technology systems combine to deliver a specialist full-service biotech CRO solution.”
Novotech also recently produced a new publication for biotechs considering China for their clinical research, and the relevant processes required for global regulatory approvals. The report details regulatory requirements for biotechs including NDA and IND processes as well as ex- US research guidance for a successful US FDA approval pathway. Novotech provides the relevant regulatory knowledge and drug development pathways specifi cally designed to support the US FDA approval process, avoiding delays and additional costs.
More information online:
ilmt.co/PL/r1eK 59489pr@reply-direct.com
Key Appointment for New Base in South Korea
Nexeon, a leading battery materials developer and manufacturer, has extended its presence in Asia with the opening of an offi ce in the Gangnam district of Seoul, South Korea, which complements the offi ce and development facility based in Yokohama, Japan, established in 2016.
Michael Choi (pictured) joins
Nexeon as Head of Asia Business Development, with a background in the lithium-ion battery industry and automotive sector. Michael will be responsible for sales and business development in Asia where major manufacturers are making strides by adopting new technologies such as silicon anodes for rechargeable batteries.
Previously Sales Director of Korea and Southeast Asia at Imerys Graphite & Carbon, where he generated signifi cant growth through development of long-term business relationships and enhanced supply chain management.
Benchtop Research Lowers Barrier to Clinical Translation
Scientists at the Australian National Phenome Centre (ANPC) at Murdoch University have detected and quantifi ed newly discovered biomarkers of SARS-CoV-2 acute infections and of ‘Long COVID’ using a benchtop Fourier Transform-nuclear magnetic resonance (FT-NMR) spectrometer with a permanent magnet, effectively lowering clinical translation of this epidemiological and diagnostic research technology.
Under the direction of Professor Jeremy Nicholson, the research found that the unique signatures and quantifi cation of the infl ammatory biomarkers developed on a 600MHz Bruker Avance IVDr NMR system could be reproduced on the 80 MHz Bruker Fourier80 Benchtop FT- NMR spectrometer.
Combining benchtop NMR with high-fi eld NMR enables clinical translation to extend the reach of this powerful technology to suit the differing clinical and research market needs.
The ANPC-Bruker collaboration used a sophisticated J-edited diffusional (JEDI) NMR experiment on the Fourier 80 to obtain quantitative signatures of two biomarker signals from N-acetylated glycoprotein (Glyc) and a novel supramolecular phospholipid composite (SPC) from phospholipids in lipoproteins. This was enhanced by a combination of relaxation, diffusion and J-editing properties of the JEDI experiment that attenuate contributions from other molecular species in plasma. This JEDI experiment also said to have demonstrated excellent
discrimination of COVID-19 from control patients.
The novel Glyc/SPC ratio measurement has emerged as a useful molecular biomarker of infl ammation in Long COVID, which could signifi cantly improve current clinical and therapeutic understanding of the acute disease and of Long COVID.
ProfessorJeremy Nicholson, Director of the ANPC, commented: “Our major goal is to detect new disease signatures and translate them into the clinic. This involves developing innovative new technologies that will immediately benefi t human health, whilst laying a platform for future scientifi c discoveries. Quickly and effi ciently testing for informative biomarkers in large numbers of human blood samples, with easy-to-use instruments, is a major milestone, proving that NMR analysis could begin to play an important role in patient care. In the case of Long COVID, we need to measure, monitor and mitigate the disease process, and benchtop technologies will be an important part of delivering that translational mission at the population level.
“We believe these fi ndings will facilitate work in samples from patients with SARS-CoV-2 acute infection and Long COVID using benchtop devices and we look forward to continuing our strategic partnership with Bruker into other disease areas.”
More information online:
ilmt.co/PL/m1yv 59498pr@reply-direct.com
He was also Head of Strategy at BMW Group Korea, where he led new business strategy including electric mobility to reduce CO2 emissions; and was a business planning director for batteries in EV & Energy Storage Systems at Samsung SDI, with earlier roles were at IBM and SK Innovation.
Mr Choi has a degree in Chemistry from Korea University, and an MBA from the University of Southern California.
“I am delighted to welcome Michael to Nexeon at this pivotal time in our development,” said Dr Scott Brown, CEO of Nexeon. “His industry and regional knowledge will be important in developing strong links with existing and new customers in the region.”
“I have been aware of Nexeon’s role in the development of silicon anode materials for some time, so I am very excited to become part of the team,” said Michael Choi.
More information online:
ilmt.co/PL/VonE 59485pr@reply-direct.com
Does your company sell or wish to sell laboratory products and services to the economies of Asia? Are you looking for local distributors and agents to represent you?
If so, why not advertise your products in our market-leading journal Lab Asia.
Email:
info@intlabmate.com
Business
Opportunities Asia
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80
